首页>
外国专利>
Topical Pharmaceutical composition, Process for producing the topical Pharmaceutical composition, use of topical Pharmaceutical Composition and Method for Topical Treatment of psoriasis, atopic dermatitis or chronic eczema
Topical Pharmaceutical composition, Process for producing the topical Pharmaceutical composition, use of topical Pharmaceutical Composition and Method for Topical Treatment of psoriasis, atopic dermatitis or chronic eczema
Claim 1: a toxic pharmaceutical ingredient characterized by: (a) methyltrinitrate, a salt thereof or a pharmaceutically acceptable hydrate; (b) methyldioxymethanol; (c) methyldioxocarboxylate; and (d) an acceptable prodrug. 11. Claim 2: the toxic drug ingredient as claimed in claim 1, which is characterized by that methaqualone is monohydrate. Claim 3: according to one of the 1-2 requirements, namely, mequinone is a trace element. Challenge 4: toxic ingredients,According to the third claim, the claim is characterized by the fact that metrinitrate is in the form of particles, 100 per cent of which are particles with a diameter of less than 30 mm. Claim 6: according to one of the requirements 1 to 5, i.e. the content of methaqualone is 0.05% to 2% of the total weight of the component, claim 8: according to the first requirement, the toxic composition of the substance, A-bisabolol is characterized by a concentration of 0.1% to 10% of its total weight.According to requirement 1 characterized by the fact that alachlor content is 0.1-10% by weight, requirement 13: according to one of requirements 1-12, the toxic composition of alachlor, It is characterized by at least: (a) an aqueous phase composed of antioxidant, gel, humectant and water vehicle; (b) an oil phase composed of emulsifier, surface agent and oil vehicle. Claim 14: the toxic drug ingredient of claim 13,It is characterized by the selectivity of aqueous phase: acidifier, alkaline agent and preservative. Claim 25: toxic pharmaceutical ingredients referred to in claims 1 to 14, which are characterized by the pharmaceutical form of dairy products, gels or emulsions; claim 32: toxic pharmaceutical ingredients referred to in claim 30, which are characterized by: (a) Water phase containing 0.01-0.5% butylhydroxyethanol (bah);0.01% to 1.0% of dihydrate (dihydrate disodium);1 to 20% glycerol; and 45 to 80% water; by total weight of the composition, and (b) an oil phase consisting of 5 to 20% of ketostearyl alcohol and polyethylene glycol stearate; 0.5 to 5% sorbitan monostearate and polysorbate; and 1.0 to 10.0% liquid petrolatum (liquid paraffin or mineral oil);in total weight of the composition. Claim 35: Production process of the topical pharmaceutical composition as defined in one of claims 1 to 33, characterized in that it comprises the steps: (a) preparation of the oil phase consisting of: (i) mixing the oil phase compounds; and (ii) heating the mixture at 60-75 ° C under constant stirring, until complete melting of the compounds; (b) preparation of the aqueous phase constituted by; (i) mixing the compounds of the aqueous phase; and (ii) heating the mixture at 60-75 ° C under constant stirring; (c) incorporate allantoin and a-bisabolol into the oil phase;(d) formation of the cream consisting of (i) incorporating the aqueous phase, stage b, into the oil phase, stage a, and (ii) cooling the dough to 35-45 ° C, under constant stirring; and (e) incorporation of methotrexate. Claim 38: Method of topical treatment of psoriasis, atopic dermatitis or chronic eczema characterized by the application of an appropriate amount on the skin lesions of the pharmaceutical composition as defined in one of claims 1 to 33.
展开▼
